Articles tagged with Glioblastomas
Researchers at McGill University Health Centre found a gene called EGFRvIII that changes the content of messages exchanged between cells, leading to aggressive brain cancer glioblastoma. This discovery holds promise for developing tests and tailored treatments for patients with glioblastoma.
A team of University of Arizona researchers discovered a protein called WIF-1 that might increase survival in glioblastoma patients. Long-term survivors rely on genes that suppress the Wnt signaling pathway, which fuels tumor growth. The study aims to create a drug targeting this pathway for more precise treatment.
Researchers at Virginia Tech have discovered a drug that can block the spread of glioblastoma, the deadliest form of brain cancer, by halting the rapid movement of fluid within the body. The breakthrough finding could lead to improved treatment options for patients with glioblastoma.
Researchers have developed a new tool to study genetic switches in glioblastoma tumors, which drive cancer growth and survival. The new technique uses ChRO-seq data to classify tumors into subtypes based on active switches, with potential applications in predicting patient outcomes and developing new therapies.
A nationwide Finnish study found that brain cancer survival has improved overall, with younger patients experiencing significant gains in median survival time. However, elderly patients saw minimal improvement, highlighting the need for more effective treatment strategies for this growing patient population.
Researchers at Barrow Neurological Institute have developed a new clinical trial regimen for treating glioblastoma, a complex brain tumor. The study demonstrates the ability of the drug AZD1775 to penetrate brain tissue and provide clinically-relevant activity against human glioblastoma.
Researchers have successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells in mice, offering a potential new treatment option. The vaccine demonstrated effectiveness in delaying tumor development and prolonging survival time in mouse models.
Researchers at UTMB successfully adapted a Zika virus vaccine to target and kill glioblastoma, the deadliest form of brain tumor. The altered vaccine effectively destroyed cancerous brain cells in mice without harming healthy ones.
Scientists at Virginia Tech Carilion Research Institute have identified a potential strategy in fighting brain cancer by targeting a gene associated with circadian rhythms. Inhibiting this gene may inhibit cancer stem cells from renewing themselves and differentiating into glioblastoma cells.
The Ben and Catherine Ivy Foundation has partnered with Barrow Neurological Institute to fund a $50 million effort to accelerate drug discovery and clinical testing for glioblastoma. The new Ivy Brain Tumor Center aims to provide individualized experimental therapies to malignant brain tumor patients worldwide.
Researchers identified epigenetic changes that accompany glioblastoma progression and predict patient survival. DNA methylation sequencing can be used to predict clinically relevant tumor properties.
MIT researchers develop a machine-learning model that reduces toxic chemotherapy and radiotherapy dosing for glioblastoma patients, maintaining tumor-shrinking potential while minimizing side effects. The model uses reinforced learning to favor lower doses and schedules, improving patient quality of life.
A KAIST research team identified where glioblastoma mutation drivers originate, revealing that normal SVZ tissue away from the tumor contains low-level mutations. The study suggests novel ways to treat glioblastoma and implies a new paradigm for therapeutic strategies.
Scientists have found that internal mammary chain irradiation and anthracycline-based chemotherapy increase cardiovascular disease risks, while a new test may detect colorectal cancer in primary care. Researchers also discovered circulating tumor cell clusters in human glioblastoma, suggesting a new target for treatment
A study published in PLOS ONE found that different mutations in the PIK3CA gene drive glioblastoma growth, but not a single targeted drug. However, combination therapies show promise, particularly with buparlisib and selumetinib.
Researchers have found that the EGFR A289 mutation in glioblastoma multiforme tumors is susceptible to the Ludwig-developed antibody drug mAb806, which has shown promising results in clinical trials. The study suggests that this broader class of brain cancers may be targeted by the antibody drug.
A study published in Cancer Cell found a rare EGFR mutation, A289D/T/V, driving more aggressive brain tumors with poorer survival rates. Researchers discovered that targeting this mutation with the monoclonal antibody drug mAb806 may reduce tumor growth and extend lives.
The California Institute for Regenerative Medicine (CIRM) has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy. The trial is expected to star...
A new study found that an experimental drug called AZ32 selectively sensitizes brain tumors to radiation, extending the survival of mouse models with human glioblastoma multiforme. The combination therapy forced GBM cells to undergo mitotic catastrophe, leading to cell death.
A recent study reveals that dying glioblastoma cells can communicate with remaining tumor cells through extracellular vesicles, increasing aggressiveness and therapy resistance. This mechanism may provide a new target for novel cancer therapies to treat glioblastoma and potentially other cancer types.
A study led by Diogo Castro discovered a genetic programme that controls the invasiveness of glioblastoma tumors. The researchers found that Zeb1, a previously known molecule involved in glioblastoma invasiveness, plays a crucial role in enabling cancer cells to invade surrounding brain tissue.
A new atlas maps out comprehensive information on glioblastoma at the cellular and molecular levels, aiming to improve diagnosis and treatment. The atlas, created by an international team led by Jill S. Barnholtz-Sloan, provides a road map of different cells and potential molecular changes in glioblastoma tumors.
A quartet of NFCR scientists publishes papers on possible bases for brain cancer treatments and insight into somatic mutations, advancing understanding of glioblastoma multiforme and its resistance to anti-angiogenesis drugs. The findings also identify a potential therapeutic strategy using MDA-9/Syntenin.
Salk Institute researchers have generated aggressive glioblastoma multiforme tumors in human cerebral organoids using CRISPR-Cas9 tool. The new model could be used to study tumor progression, investigate new drugs or personalize treatments for patients.
A new study found that some types of glioblastoma tumors shed extracellular vesicles containing PDL-1, which helps them evade the immune system. The presence of PDL-1 DNA in blood samples from patients with glioblastoma may serve as a biomarker for the disease.
A new microfluidic device developed by Massachusetts General Hospital may help monitor a tumor's response to therapy and provide detailed information to guide treatment choice. The device isolated tumor-specific EVs from all 13 patients with glioblastoma multiforme, identifying key genetic and molecular information.
A phase I clinical trial found that the altered adenovirus DNX-2401 allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer. The virus triggered an immune response, leading to tumor reduction and complete responses in some patients.
A Clemson University undergraduate researcher has identified 22 genes associated with aggressive brain cancer glioblastoma. The discovery was made using a novel computer software that analyzed genomic data from two online public databases, revealing co-expression relationships between the genes.
Researchers found that combining temozolomide with the enzyme inhibitor SLC-0111 significantly regressed human-derived glioblastoma, improving patient outcomes. The treatment strategy targets carbonic anhydrase 9, a membrane enzyme involved in tumor growth.
Researchers found adding hydroxyurea to current chemotherapy protocol significantly increased survival in animal models of glioblastoma, a deadly brain cancer. The combination led to a significant increase in survival and even induced remission in some cases.
Glioblastoma, a type of brain cancer with a grim prognosis, may be treatable more effectively when administered at specific times of day. Researchers found that the circadian rhythm controls daily rhythms in a key protein associated with tumor growth, and inhibiting its activity can reduce invasive properties.
Scientists have discovered a novel mechanism that prevents glioblastoma development through the modulation of EFGR expression by RanBP6. The study reveals that silencing of RanBP6 promotes glioma growth by upregulating EGFR expression, while reconstitution of RanBP6 leads to reduction in tumor growth.
A Northwestern Medicine study reveals autophagy's promoting role in malignant glioblastoma and identifies MST4 and ATG4B as key players. Inhibiting ATG4B with radiotherapy significantly slows tumor growth, increasing overall survival rates.
Researchers have identified a genetically distinct subpopulation of patients with glioblastoma that is particularly sensitive to drugs like cilengitide. The strategy uses a gene profile alone to predict which tumors are susceptible to αvβ3 blockade, offering a new therapeutic target for precision medicine in brain cancer treatment. Thi...
Ludwig Cancer Research researchers will present findings on cancer cell metabolism, tumor microenvironment, and potential therapeutic targets. They will also discuss the use of immunotherapy to treat brain cancer, including results from a Phase 2 clinical trial.
Researchers have developed a new therapy that blocks the TRF1 protein, which is essential for protecting telomeres in glioblastoma cells. This approach has shown promising results in mouse models, with a significant increase in survival rates and reduction in tumour growth.
Preclinical studies demonstrate onalespib's effectiveness in inhibiting HSP90, reducing cell-survival proteins and tumor growth. The agent shows promise as a single treatment or in combination with temozolomide for glioblastoma patients.
Researchers have developed a comprehensive genomic sequencing approach that guides timely treatment for recurring brain cancer, resulting in extended progression-free survival. Two patients survived over a year without disease recurrence, demonstrating the potential of precision medicine in aggressive and refractory tumors.
Researchers found that arsenic trioxide can be a powerful therapy for glioblastoma multiforme, extending patient survival by three to four times. The treatment targets specific genomic signatures of brain tumor cells, allowing for precision medicine and matching the right drug to the right patient.
A research team led by Dr. Claudia Barros aims to understand the cellular changes leading to glioblastoma brain tumor development. Using a Drosophila fruit fly model, they visualize cancer stem cells and identify early molecular changes.
Scientists at Mount Sinai & Sema4 validated a biomarker indicative of glioblastoma patient prognosis and likely response to therapies. BUB1B-sensitive tumors had significantly worse prognosis but were more likely to respond to many drugs already in clinical use.
Patients diagnosed at high-volume centers are up to 40% more likely to receive treatment for glioblastoma and live approximately three and a half months longer than those treated at low-volume centers. The study suggests that patients benefit from care at hospitals treating a high number of brain tumor patients.
Researchers have found that Zika virus preferentially infects and kills glioblastoma stem cells compared to other cell types. A mutant strain of the virus shows promise in slowing tumor growth and extending lifespan when combined with chemotherapy, offering a new potential treatment for brain cancer.
Researchers discovered a novel molecular mechanism that maintains glioma stem cells, which are responsible for tumorigenesis, treatment resistance, and tumor recurrence in glioblastoma. A small molecule inhibitor CMP3a selectively inhibits NEK2 kinase activity to promote tumor growth and radiation resistance.
Researchers found genetically modified CAR T cells successfully migrated to and penetrated glioblastoma tumors, but triggered an immunosuppressive tumor microenvironment. To overcome resistance, existing immunotherapies targeting checkpoint inhibitors may be necessary.
Research identified PTPRZ as a crucial enzyme for glioblastoma's maintenance and tumorigenicity. Pharmacological inhibition of PTPRZ shows promise in treating malignant gliomas.
A study published in Cell Reports found that altering the levels of microRNA miR-128 can induce a more homogeneous subtype of glioblastoma cells, making them more responsive to treatment. This discovery opens the door for using miR-128 as a therapeutic agent.
A research team has revealed intrinsic gene expression patterns of glioblastoma tumors, which could drive more effective treatments. The study found that tumor microenvironment cells contribute to the 'ecosystem' of hundreds of GBM tumors, influencing treatment outcomes and response to immunotherapy.
Researchers found that PTEN, a frequently deleted tumor suppressor gene in cancer, can regulate oncogene expression by increasing the deposition of DAXX and H3.3 onto chromatin. The study showed that eliminating both genes led to a synthetic growth defect, slowing down tumor growth.
Recent studies by TGen and UNC Lineberger researchers provide insight into glioblastoma's evolution and how to combat this aggressive brain tumor. The studies reveal that mutations affect how cancer starts and evolves, while combining drugs targeting PI3K and MAPK pathways show promise as a therapeutic approach.
A phase one study of 11 patients with glioblastoma who received injections of an investigational vaccine therapy and an approved chemotherapy showed the combination to be well tolerated while also resulting in unexpectedly significant survival increases. The researchers found that the combination significantly slowed the progression of...
A vaccine combining with high-dose chemotherapy improved glioblastoma patients' progression-free and overall survival. The vaccine targeted CMV antigen pp65, which is expressed in 90% of GBM tumors.
Lauren Sciences LLC has received the second grant from Voices Against Brain Cancer to continue developing LAUR-401, its innovative V-Smart Nanomedicine for Glioblastoma Multiforme. The award confirms the successful development of LAUR-401 and anticipates its potential as a transformative therapeutic for brain cancer patients.
Researchers found a way to inhibit glioblastoma growth by targeting neurodevelopmental transcription factors, which drive brain tumor growth. A chemotherapy drug called mithramycin can prevent further tumor growth with minimal side effects.
A new classification system for glioblastoma, a lethal brain cancer, has been developed by incorporating molecular variables. The refined model significantly improves the prognosis of patients treated with radiation and temozolomide, offering better clinical decision-making options.
A study by TGen has identified aurintricarboxylic acid (ATA) as a compound that can improve drug development against glioblastoma. ATA blocks the chemical cascade that allows glioblastoma cells to invade normal brain tissue and resist chemotherapy and radiation therapy.
A study suggests targeting the RAD51 protein could increase the effectiveness of radiotherapy in killing off glioblastoma cells, a subgroup of brain tumour cells that are resistant to treatment. Glioblastoma is the most common and aggressive type of primary brain tumour in adults, with a poor prognosis.
A new research from Michigan Medicine supports combining immune checkpoint blockade with gene therapy to fight gliomas. The approach showed stronger results when used in combination with either depletion of immunosuppressive cells or immune checkpoint blockade.
Researchers from the National Foundation for Cancer Research (NFCR) have discovered a new pharmacological agent to treat glioblastoma multiforme, a deadly brain cancer. The treatment has shown profound survival benefits in pre-clinical models when combined with radiation.
Researchers at Stanford University School of Medicine found that a subgroup of glioblastoma patients with highly vascularized tumors benefited from anti-angiogenic therapies, living an average of one year longer than those without. The study highlights the importance of properly categorizing tumors to personalize treatment.